Literature DB >> 7721822

Inhibition of mammalian squalene synthetase activity by zaragozic acid A is a result of competitive inhibition followed by mechanism-based irreversible inactivation.

S Lindsey1, H J Harwood.   

Abstract

Squalene synthetase (SQS, EC 2.5.1.21) catalyzes the first committed step in the formation of cholesterol and thus represents an ideal site for selectively inhibiting sterol formation. Previous studies have demonstrated that the fungal metabolite, zaragozic acid A (ZGA-A), inhibits SQS activity by mimicking the substrate farnesyl pyrophosphate, the reaction intermediate presqualene pyrophosphate, or both, through a process that confers increased apparent potency in the presence of reduced enzyme concentrations, an observation consistent with either tight binding reversible competitive inhibition or mechanism-based irreversible inactivation. The studies outlined in this report provide multiple lines of evidence indicating that ZGA-A acts as a mechanism-based irreversible inactivator of SQS. 1) Inhibition of SQS by ZGA-A is dependent on the [SQS] present in the incubation reaction, and this inhibition is time-dependent and follows pseudo-first order reaction kinetics, exhibiting kobs values that range between 2 x 10(-4)/s and 23 x 10(-4)/s for [ZGA-A] within the log-linear range of the inhibition curve, and a bimolecular rate constant of 2.3 x 10(5) M-1s-1.2) SQS activity is titratable by ZGA-A, such that for each [ZGA-A] evaluated, inactivation exhibits a threshold [SQS] whereby enzyme activity at lower [SQS] is totally inhibited. 3) Time-dependent inactivation exhibits saturation kinetics with a Km for the process of 2.5 nM, which is approximately equal to the IC50 for SQS inhibition under these conditions, suggesting that inactivation results from selective modification of a functional group of the enzyme active center rather than from a nonspecific bimolecular reaction mechanism and that most, if not all of the inhibition results from irreversible inactivation. 4) Saturable, time-dependent inactivation occurs with similar inactivation kinetics for both the microsomal and trypsin-solubilized forms of the enzyme, indicating that irreversible inactivation by ZGA-A is not a consequence of membrane modification but is a direct effect of the inhibitor on the enzyme. 5) Inactivation is biphasic, exhibiting a rapid ("burst") phase followed by a second, pseudo-first order phase, similar to that previously noted for irreversible inactivators in other enzyme systems, and occurs even in the presence of 5 mM concentrations of the nucleophylic scavenger dithiothreitol, suggesting that the reaction between ZGA-A and SQS occurs at or near the active center prior to diffusion of reactive species out of the catalytic cleft. 6) Inactivation can be prevented through competition with the substrate, farnesyl pyrophosphate, further identifying the active center as the site of modification.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7721822     DOI: 10.1074/jbc.270.16.9083

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  10 in total

1.  Kinetic characterization of squalene synthase from Trypanosoma cruzi: selective inhibition by quinuclidine derivatives.

Authors:  Marco Sealey-Cardona; Simon Cammerer; Simon Jones; Luis M Ruiz-Pérez; Reto Brun; Ian H Gilbert; Julio A Urbina; Dolores González-Pacanowska
Journal:  Antimicrob Agents Chemother       Date:  2007-03-19       Impact factor: 5.191

2.  Synthesis and biological activity of new iodoacetamide derivatives on mutants of squalene-hopene cyclase.

Authors:  Maurizio Ceruti; Gianni Balliano; Flavio Rocco; Alexander Lenhart; Georg E Schulz; Francesco Castelli; Paola Milla
Journal:  Lipids       Date:  2005-07       Impact factor: 1.880

3.  19-Azasqualene-2,3-epoxide and its N-oxide: metabolic fate and inhibitory effect on sterol biosynthesis in Saccharomyces cerevisiae.

Authors:  P Milla; F Viola; M Ceruti; F Rocco; L Cattel; G Balliano
Journal:  Lipids       Date:  1999-07       Impact factor: 1.880

4.  YM-53601, a novel squalene synthase inhibitor, reduces plasma cholesterol and triglyceride levels in several animal species.

Authors:  T Ugawa; H Kakuta; H Moritani; K Matsuda; T Ishihara; M Yamaguchi; S Naganuma; Y Iizumi; H Shikama
Journal:  Br J Pharmacol       Date:  2000-09       Impact factor: 8.739

5.  Inhibition of squalene synthase and squalene epoxidase in tobacco cells triggers an up-regulation of 3-hydroxy-3-methylglutaryl coenzyme a reductase.

Authors:  Laurent F Wentzinger; Thomas J Bach; Marie-Andrée Hartmann
Journal:  Plant Physiol       Date:  2002-09       Impact factor: 8.340

6.  Cloning, solubilization, and characterization of squalene synthase from Thermosynechococcus elongatus BP-1.

Authors:  Sungwon Lee; C Dale Poulter
Journal:  J Bacteriol       Date:  2008-03-28       Impact factor: 3.490

7.  Differential inhibition of host cell cholesterol de novo biosynthesis and processing abrogates Eimeria bovis intracellular development.

Authors:  Penny H Hamid; Jörg Hirzmann; Carlos Hermosilla; Anja Taubert
Journal:  Parasitol Res       Date:  2014-09-10       Impact factor: 2.289

8.  Differential roles of the mevalonate pathway in the development and survival of mouse Purkinje cells in culture.

Authors:  Andrew Barszczyk; Hong-Shuo Sun; Yi Quan; Wenhua Zheng; Milton P Charlton; Zhong-Ping Feng
Journal:  Mol Neurobiol       Date:  2014-06-29       Impact factor: 5.590

9.  A squalene synthase-like enzyme initiates production of tetraterpenoid hydrocarbons in Botryococcus braunii Race L.

Authors:  Hem R Thapa; Mandar T Naik; Shigeru Okada; Kentaro Takada; István Molnár; Yuquan Xu; Timothy P Devarenne
Journal:  Nat Commun       Date:  2016-04-06       Impact factor: 14.919

10.  Besnoitia besnoiti infection alters both endogenous cholesterol de novo synthesis and exogenous LDL uptake in host endothelial cells.

Authors:  Liliana M R Silva; Dieter Lütjohann; Penny Hamid; Zahady D Velasquez; Katharina Kerner; Camilo Larrazabal; Klaus Failing; Carlos Hermosilla; Anja Taubert
Journal:  Sci Rep       Date:  2019-04-30       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.